Gain Therapeutics
GANX
38 hedge funds and large institutions have $7.7M invested in Gain Therapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 6 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
9% more funds holding
Funds holding: 35 → 38 (+3)
0.57% less ownership
Funds ownership: 12.65% → 12.08% (-0.57%)
35% less capital invested
Capital invested by funds: $11.9M → $7.7M (-$4.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$357K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$235K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$182K |
| 4 |
Morgan Stanley
New York
|
+$134K |
| 5 |
Jane Street
New York
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$5.36M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$171K |
| 3 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$82.8K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$23K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$19.9K |
GANX Hedge Fund Activity: Q3 2025 in Review
38 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2025, worth a combined $7.7M — down 35% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GANX positions and 6 closed out — a net gain of 3 holders — while 14 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $357K. The largest seller was Gotham Asset Management, exiting entirely with an estimated $5.36M sold.
- 38 institutional investors held Gain Therapeutics (GANX) as of Q3 2025, up from 35 in Q2 2025.
- Funds reported $7.7M of Gain Therapeutics stock for Q3 2025, down 35% quarter-over-quarter.
- 9 funds opened new Gain Therapeutics positions in Q3 2025 and 6 closed out, a net change of +3 holders.
- The largest Gain Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $357K added.
- The largest Gain Therapeutics seller in Q3 2025 was Gotham Asset Management, an estimated $5.36M sold.
Based on aggregated 13F filings for Q3 2025.